Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Get Free Report)’s stock price was down 5% during trading on Thursday . The company traded as low as $1.89 and last traded at $2.09. Approximately 370,047 shares traded hands during trading, an increase of 217% from the average daily volume of 116,627 shares. The stock had previously closed at $2.20.
Phio Pharmaceuticals Trading Down 5.0 %
The stock’s 50 day moving average is $2.71 and its two-hundred day moving average is $3.53. The stock has a market capitalization of $2.20 million, a price-to-earnings ratio of -0.19 and a beta of 1.49.
About Phio Pharmaceuticals
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.
Further Reading
- Five stocks we like better than Phio Pharmaceuticals
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Top 3 Investment Themes to Watch for in 2025
- The Role Economic Reports Play in a Successful Investment Strategy
- Mega Buybacks in 2025: Why These 3 Leading Stocks Are Buys
- Stock Market Upgrades: What Are They?
- AMD vs. NVIDIA: The Better Semiconductor Bet for 2025
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.